Welcome to our dedicated page for TENAX THERAPEUTICS SEC filings (Ticker: TENX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tenax Therapeutics filings document a Phase 3, development-stage pharmaceutical company developing cardiopulmonary therapies, including TNX-103 (oral levosimendan) for PH-HFpEF. Recent 8-K reports record financial results, clinical program updates for LEVEL and LEVEL-2, intellectual-property notices, and amendments to levosimendan license rights, including expanded worldwide rights for orally administered products.
Proxy and current-report filings also describe Nasdaq-listed common stock, executive appointments, employment and compensation arrangements, equity awards, governance matters, and named-executive pay disclosures. These records frame the company's capital structure, leadership responsibilities, material agreements, and clinical-stage operations around levosimendan development and commercialization rights.
Tenax Therapeutics director June Sherie Almenoff reported a new stock option grant and her current equity holdings in a Form 4 filing. On January 9, 2026, she was granted a stock option for 30,000 shares of common stock at an exercise price of $13.30 per share. This option becomes exercisable on January 9, 2027 and expires on January 9, 2036, and was reported as held directly.
The filing also lists previously awarded stock options held directly, covering 100,000 shares (exercisable from December 10, 2025 to December 10, 2034), 80,000 shares (exercisable from July 1, 2026 to July 1, 2035), and two very small option positions of 4 shares each. In addition, 1,993 shares of common stock are reported as held indirectly through Meadowlark Management, LLC, with a statement that Almenoff disclaims beneficial ownership except to the extent of her pecuniary interest.
Tenax Therapeutics director Declan Doogan reported a new stock option grant. The Form 4 shows that on 01/09/2026 he received a stock option to buy 30,000 shares of Tenax common stock at an exercise price of $13.3 per share. The option is shown as exercisable on 01/09/2027 and expiring on 01/09/2036, and is held directly.
In addition to this grant, the filing lists previously awarded stock options covering 100,000 shares exercisable from 12/10/2025 and 80,000 shares exercisable from 07/01/2026, along with two very small option positions of 4 shares each. Doogan also directly holds 2,274 shares of Tenax common stock following the reported transactions.
Tenax Therapeutics director Robyn Hunter reported a new stock option grant in a Form 4 filing. On January 9, 2026, Hunter received stock options to buy 30,000 shares of common stock at an exercise price of $13.30 per share, with no cash paid for the option itself.
The options become exercisable on January 9, 2027 and expire on January 9, 2036. After this grant, Hunter directly holds 30,000 of these newly reported derivative securities, alongside other previously granted stock options in Tenax Therapeutics.
Tenax Therapeutics, Inc. reported an update to the employment terms of its Chief Medical Officer, Dr. Stuart Rich. Effective January 1, 2026, Dr. Rich will devote an average of four days per week to his duties as Chief Medical Officer under a second amendment to his Executive Employment Agreement.
His annual base salary will be prorated to reflect this modified work schedule. The amendment was approved by the Board of Directors on December 22, 2025, and formally entered into on January 6, 2026. The complete terms are set out in the Second Amendment to Executive Employment Agreement, filed as Exhibit 10.1.
Tenax Therapeutics reported new clinical progress for its lead drug candidate TNX-103 in patients with pulmonary hypertension related to heart failure with preserved ejection fraction. A planned blinded sample size re-estimation for the LEVEL Phase 3 trial showed the study is powered at well over 90% to detect a 25 meter change in 6-minute walk distance, the primary measure of effectiveness. This supports keeping the existing enrollment target and previously communicated timelines for finishing enrollment and reporting topline data. Tenax also started LEVEL-2, a second global Phase 3 registrational trial of TNX-103 in the same patient population, indicating a broader late-stage development program.
Tenax Therapeutics, Inc. director and Chief Medical Officer reported recent open-market purchases of the company’s common stock and detailed his equity holdings. On December 2, 2025, he bought 1,000 shares at a weighted average price of $9.0059, followed by 1,500 shares at $9.0786 on December 3 and 2,500 shares at $9.1992 on December 4.
After these transactions he directly owns 2,766 common shares and has additional indirect holdings of 2,500, 1,194, and 1,194 shares through specified family trusts, for which he disclaims beneficial ownership beyond his pecuniary interest. He also beneficially owns stock options over 157, 63, 119, 500,000, and 625,000 shares at stated exercise prices, with vesting tied to time-based schedules and milestones such as a Phase 3 clinical trial, FDA-related steps, and continued employment.
Tenax Therapeutics, Inc. (TENX) reported insider activity by its CEO and director, who bought common stock on three consecutive days. On 11/18/2025, the insider purchased 1,612 shares at a weighted average price of $7.7546, followed by 455 shares at $7.5091 on 11/19/2025 and 538 shares at $7.5887 on 11/20/2025. After these open‑market purchases, the insider beneficially owned 2,605 shares of Tenax common stock directly.
The filing also lists existing stock options held by the insider. These include options exercisable for 157 shares of common stock expiring on 07/06/2031, 125 shares expiring on 06/09/2032, and 437 shares expiring on 05/17/2034, along with larger grants for 1,250,000 shares at an exercise price of $5.94 expiring on 12/10/2034 and 1,400,000 shares at $5.89 expiring on 05/16/2035. The vesting of these options is tied to continued employment and follows specified annual or monthly schedules.
Tenax Therapeutics, Inc. (TENX) director reported open-market purchases of common stock and corrected how those shares are reported. On 11/17/2025, an indirect account bought 93 shares at $7.15 per share, and on 11/18/2025 it bought 1,900 shares at a weighted average price of $7.5157, for a total of 1,993 shares held through Meadowlark Management, LLC. This amended Form 4 changes the ownership form for those 1,993 shares from direct to indirect, clarifying that the director disclaims beneficial ownership beyond her economic interest.
Tenax Therapeutics (TENX) reported an insider stock purchase by its Interim CFO. On 11/17/2025, the officer bought 2,000 shares of common stock directly and now holds 2,000 shares in their own name. On the same date, they reported additional purchases of 1,000 shares held indirectly through a child and 5,000 shares held indirectly through a spouse.
The direct shares were acquired at a weighted average price of $7.337, with trades executed between $7.14 and $7.43. The spouse’s shares were bought at a weighted average price of $7.228, with trades between $7.17 and $7.30, and the child’s shares at $7.35. All transactions were coded as open-market purchases.
Tenax Therapeutics, Inc. (TENX) director reports open‑market share purchases. A company director filed a Form 4 disclosing two common stock purchases on 11/17/2025 and 11/18/2025. The director bought 93 shares at $7.15 per share and another 1,900 shares at a weighted average price of $7.5157, for a total of 1,993 common shares held directly after these trades. The filing also lists stock options giving the right to buy Tenax common stock, including 100,000 options at an exercise price of $5.94 exercisable from 12/10/2025 to 12/10/2034, and 80,000 options at an exercise price of $5.75 exercisable from 07/01/2026 to 07/01/2035, along with two smaller legacy option grants of 4 shares each.